Low, High HDL Linked to Risk for Age-Related Macular Degeneration
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
TUESDAY, May 27, 2025 -- Low and high high-density lipoprotein (HDL) are associated with an increased risk for age-related macular degeneration (AMD), according to a study published in the June issue of Ophthalmology.
Jimmy S. Chen, M.D., from the Shiley Eye Institute at the University of California San Diego in La Jolla, and colleagues conducted a cross-sectional retrospective data analysis involving 5,028 healthy participants and 2,328 patients with AMD from the All of Us research program to examine associations between clinical and genetic-based factors related to lipoprotein metabolism and the risk for AMD.
The researchers found that statin use and low and high HDL were significantly associated with an increased risk for AMD in a multivariable regression analysis. Certain HDL-associated single nucleotide polymorphisms (SNPs) increased the risk for AMD in multivariate regression. LPA, a major protein associated with lipoprotein(a), was identified as a novel SNP that is associated with an increased risk for AMD (odds ratio, 1.37).
"These findings highlight an exciting application of the wealth of clinical and genetic data in the All of Us dataset to highlight novel associations with the retinal disease pathophysiology of AMD," the authors write.
One author disclosed ties to Topcon, which manufactures equipment for ophthalmology and surveying.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2025-05-28 12:00
Read more

- Mouth Taping For Better Sleep? Little Benefit, Lots Of Risk, Review Says
- Unconditional Cash Transfer May Increase Breastfeeding Rates
- IDeate-Esophageal01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Certain Patients with Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
- Race, Ethnicity Influence Sodium Sources, Sodium Reduction Behavior
- 1 in 10 Doctors is Burned Out
- Rates of Fentanyl Nonfatal Overdose ED Visits Rose Through Third Quarter of 2023
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions